Home Patient Safety

Publications & Speaking

Selected presentations, publications and professional contributions.

Navigate to the next section

Presentations

  • BIA and MHRA event on Risk Management across the Product Lifecycle (London, Feb 2008): “Requirement for risk management plan – Safety specifications. Industry perspective.”
  • Medicines for Children- Clinical and Regulatory update (Cologne, Jul 2009): “Safety and risk management in clinical trials with children.”
  • World Drug Safety Congress Europe (London, Sep 2009): “Industry perspective: Maintaining pace with regulators and the evolving industry safety strategies to meet regulatory developments.”
  • World Drug Safety Congress Europe (London, Sep 2011): Member of the advisory board. “Maintaining pace with evolving industry safety strategies to meet regulatory and external developments. Challenges in safety surveillance, signal detection, risk management, and monitoring of the benefit-risk relationship.”
  • World Drug Safety Congress (Boston, USA; Apr 2012). “PSURS- How can we ensure that we do this in a smarter way? »   and panel member for “Overcoming transparency difficulties in pharmacovigilance”.
  • World Drug Safety Congress Europe (London,12-13 Sep 2012): “Transparency in the EU” and Chair of the 12 September sessions.
  • Life Science Network Basel, 25 September 2014: “Pharmacovigilance. Role and added value. Impact of the business on PV and impact of PV on the business.”
  • World Drug Safety Congress Europe, 12-13 September 2017, Berlin.  » Latest developments in signal management and their implications ».
  • World Drug Safety Congress 10-11 September 2018, Amsterdam. « Drug safety in children »
  • World Drug Safety Congress Americas, April 15-17 April 2019, Philadelphia (USA). Moderator of round table discussion: « Signal detection: data sources, challenges, and innovative approaches »
  • World Drug Safety Congress September 2019, Amsterdam. Moderator roundtable « Signal detection and signal management » and Chair session « Signal detection and signal management »
  • World Drug Safety Congress Americas, 01-02 Sep 2020 (virtual). « EU surveillance requirements: adapting traditional PV strategies into device safety practices to meet newly issued government safety standards »
  • World Drug Safety Congress 14-15 October 2020 (virtual), Amsterdam. Moderator of round table « Signal detection in small and medium sized companies »
  • World Safety Congress Europe, Amsterdam, Oct 2021. Chair of sessions on Risk Management.
  • World Drug Safety Europe Congress, 27-29 September 2022, Amsterdam. Chair of sessions on signal detection and signal management.
  • World Drug Safety Europe Congress, 04-05 October 2023, Amsterdam. Digital transformation. “Staffing needs and structure of a PV department”.
  • World Drug Safety Europe Congress, 09-10 October 2024, Amsterdam.  “Safety monitoring in clinical studies”.
  • Pharmacovigilance UK & EU 2025, 12-13 Feb 2025, London. Panel Discussion: “Latest updates and hot topics – A new era of Pharmacovigilance”.
  • World Drug Safety Europe Congress, 07-08 October 2025, Amsterdam.  “Independent safety monitoring in clinical trials”.

Publications

  • Chin J.G.J., Van Herpen G., Vermarien H., Wang J., Koops J. ,Scheerlinck R.,Van Vollenhoven E. Mitral valve prolapse: A comparative study with two-dimensional and Doppler echocardiography, auscultation, conventional and esophageal phonocardiography. American Journal of Noninvasive Cardiology, 1992, vol./is. 6/3(147-153), 0258-4425.
  • A Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics and antitumor activities of BAL101553, a novel tumor checkpoint controller, administered as 48-hours infusion in adult patients with advanced solid tumors. ASCO Annual Meeting June 2-6, 2017 (poster).
  • M. Osada, Y. Kuroki, P. Rueckert, A. Krebs-Bron, R. Scheerlinck, J. Sadewasser, N.Hooper, A. Becker, Y. Vugmeyster. Pharmacokinetics of xevinapant and its metabolite, D-1143-MET1, in healthy East Asian participants. Poster at annual meeting Japanese Society of Medical Oncology (JSMO), 22-24 Feb 2024.
  • J. Bourhis, L.F. Licitra, B. Burtness, A. Psyrri, R. Haddad, K. Harrington, E.W. Cohen, Y. Tao, K.A. Tiscoski, A. Matitashvili, M. Tahara,  A. Sukari, T. Rutkowski, S. Salas, H. Nauwelaerts, R. Scheerlinck, N.T. Ha, A. Schroeder, A. Rodriguez-Gutierrez, J.D. Schoenfeld.  Xevinapant or placebo plus platinum-based chemoradiotherapy in unresected locally advanced squamous cell carcinoma of the head and neck (TrilynX): A randomized, Phase III study. Journal of Clinical Oncology, Sep 2025, DOI https://doi.org/10.1200/JCO-25-00272
  • Valentina Boni, Johann S. De Bono, Hiromichi Nakajima, Hiroaki Kikukawa, Sang Joon Shin, Inkeun Park, Shigehisa Kitano, Tatiana Hernandez Guerrero, Irene Moreno Candilejo, David Olmos Hidalgo, Akira Yokomizo, Sarwan Bishnoi, Marta Gil-Martin, Rudi Scheerlinck, Giuseppe Locatelli, Burak Kuersad Guenhan, Andreas Becker, Karin Laaber, Ning Chang, Timothy A. Yap. Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the Phase 1 DDRiver 501 study. Abstract American Society of Clinical Oncology (ASCO), 29 May- 02 June 2026, Chicago